HOME >> MEDICINE >> NEWS
Phase II trial of anthrax vaccine to begin

Center for Vaccine Research needs volunteers for Phase II Trial of anthrax vaccine candidate

(Torrance, CA April 22, 2004) The UCLA Center for Vaccine Research, a leading research program at the Research and Education Institute (REI) at Harbor UCLA Medical Center, announced today that it has initiated a Phase II trial of a new anthrax vaccine, rPA102 (VaxGen, Inc.). The 13-month trial is taking place at 12 medical centers in the United States and is one of two studies of rPA102 initiated this year under a multi-year, $80.3 million U.S. government contract to VaxGen, Inc. from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

VaxGen, Inc. began developing rPA102 to address the need for an anthrax vaccine that has an improved safety profile and a more practical dosing schedule compared to the existing licensed anthrax vaccine. rPA is a synthetic protein vaccine that induces antibodies that are designed to prevent illness by neutralizing anthrax toxins. rPA102 cannot cause anthrax infection. The goal of this study is to determine the optimal formulation of the rPA vaccine that will provide an early and protective immune response.

Healthy adults, 18 to 55 years of age, who have not received an anthrax vaccine and have not been exposed to anthrax, are needed to participate in this study. Participants will need to be available for 14 visits to the clinic (Torrance) over a one-year period. Participants will be compensated up to $700 for completion of study visits.

For further information on how to take part in this trial, please call 1-800-637-8860.


'"/>

Contact: Susan Partridge, BSN, MBA
partridge@humc.edu
310-781-3630
Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (LA BioMed)
22-Apr-2004


Page: 1

Related medicine news :

1. Elan and Biogen Idec announce results from Phase III maintenance trial of Antegren
2. NIAID Phase III HIV vaccine trial to determine correlates of protection will not proceed
3. MetaPhore Pharmaceuticals initiates Phase I clinical trial of enzyme mimetic compound for oncology
4. Maret Pharmaceuticals presents promising Phase I/II clinical MARstem™ results at international symposium on new drugs in cancer therapy
5. Penn researchers announce results of Phase I trial using combretastatin drug
6. Anti-cocaine vaccine produces antibodies and is shown to be safe in Phase 1 study conducted by Yale researcher
7. Results of NUVANCE (IL-4 receptor) in Phase I/II study in asthma patients featured at AAAAI Late-Breaker Abstract and Asthma Therapy Sessions
8. ILEX Oncology & LeukoSite report results from pivotal Phase II CAMPATH (R) trial; Results suggest new hope for refractory chronic lymphocytic leukemia
9. Abgenix Reports Positive Survival Data From A Phase II Trial Of ABX-CBL In Graft Versus Host Disease
10. Immunex Advances CD40 Ligand To Phase II Clinical Trial In People With Metastatic Kidney Cancer
11. Positive Results Of Pivotal Phase III Trial With ENBREL In Patients With Early, Active Rheumatoid Arthritis

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:11/15/2018)... (PRWEB) , ... November 15, 2018 , ... Lisa ... clinical educator for Specialty MED Training will take the stage during the ... December 13-15, 2019. Dr. Vuich is leading a CME workshop hosted by Tailor ...
(Date:11/14/2018)... HERNDON, Va. (PRWEB) , ... November 14, 2018 ... ... Health and Jordan Pisarcik, Vice President, Account Management at DocASAP, will host a ... Nexus” , WHAT:, Hosted by American Medical Group Association (AMGA), the 2018 Institute ...
(Date:11/14/2018)... ... November 14, 2018 , ... For what is a first ... Therapy (EFFT) for Eating Disorders, will present an overview of the EFFT model with ... keynote speakers at the 2019 event. , Next year’s 33rd iaedp™ Symposium is ...
(Date:11/13/2018)... ... November 14, 2018 , ... REMS: Requirements, Regulation, and Enforcement:, ... — 1:30 p.m. – 3:00 p.m. ET, http://www.fdanews.com/remsrre ... enforcement tool. A constantly evolving enforcement tool. , In September the FDA added ...
(Date:11/13/2018)... ... 2018 , ... The Centers for Medicare and Medicaid Services ... seven high volume current procedural terminology (CPT) codes as potentially misvalued, amongst which ... RUC (Relative Value Update Committee) of the American Medical Association re-evaluate the work ...
Breaking Medicine News(10 mins):
(Date:11/15/2018)... , ... November 15, 2018 , ... ... in 2016 and is estimated to continue its dominance during the study period. ... Mobile exoskeleton provides mobility to the wearer while augmenting strength to lift heavy ...
(Date:11/15/2018)... ... November 15, 2018 , ... ... its participation in the California Optometric Association’s Monterey Fall Symposium. This three day ... a platform for connecting with hundreds of doctors of optometry. , For this ...
(Date:11/14/2018)... ... November 14, 2018 , ... Planet DDS ... that Hannah Cohen was joining the company as its new Vice President of ... at DaVita, one of the nation’s leading managed care providers. At DaVita, Hannah ...
Breaking Medicine Technology:
Cached News: